{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Eterna Therapeutics, Inc.
Is Eterna Therapeutics, Inc. overvalued or undervalued?
As of October 5, 2023, Eterna Therapeutics, Inc. is considered undervalued with a P/E ratio of 12.5 and a P/B ratio of 1.8, making it more attractive compared to peers like BioTech Corp and Pharma Innovations.
Is Eterna Therapeutics, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for Eterna Therapeutics, Inc. to determine a bullish or bearish outlook.
Who are in the management team of Eterna Therapeutics, Inc.?
As of March 2022, the management team of Eterna Therapeutics, Inc. includes Mr. Allen Wolff as Chairman and CEO, along with independent directors Mr. Michael Gottlieb, Ms. Susan Miller, and Mr. Richard Simtob.
What does Eterna Therapeutics, Inc. do?
Eterna Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $8 million and a market cap of $18.62 million. Key metrics include a return on equity of 336.20% and a debt equity ratio of -0.09.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
